What isKisspeptin-10FDA Status, Evidence and Risks (2026)

What kisspeptin-10 is

Kisspeptin is a hormone signal near the top of the reproductive chain. It binds a receptor called KISS1R (also GPR54) ³ and sets off the hormone cascade that starts with GnRH.

The body makes several lengths of it. The KISS1 gene encodes a 145-amino-acid protein, which is cut into kisspeptin-54, -14, -13 and -10 ³. All of them share the same last 10 amino acids. That 10-amino-acid piece is kisspeptin-10, also called metastin 45-54 ³.

The last row matters. Many headlines say "kisspeptin" without the number. In men, kisspeptin-10 lasts about 3.8 minutes in the blood ³.

Where FDA stands

1. Sept 29, 2023: added to FDA's Category 2 list for 503A pharmacies, the substances FDA says "may present significant safety risks" in compounding ¹.
2. Oct 29, 2024: FDA reviewed it for the 503A bulks list, for one use: secondary hypogonadism in men, meaning low testosterone that starts in the brain or pituitary ³. Staff said the evaluation criteria "weigh against" adding it ³.
3. Same day: the advisory committee voted 0 yes, 11 no, 0 abstentions ².
4. Today: still on Category 2 for 503A pharmacies, as of FDA's Apr 22, 2026 page ¹. Not on the 503A bulks list ⁶. Not approved by FDA for any use.

It is the last peptide on the 503A side of that list ¹. Coming off would not have meant approval anyway. Are peptides legal? covers why.

Not in the HHS policy. On Oct 28, 2026, HHS filed an interim enforcement discretion policy for compounding six peptides: BPC-157, TB-500, MOTS-c, epitalon, semax and KPV ⁷. Kisspeptin-10 is not one of them, so its status above stands, as of Oct 29, 2026. The FDA Peptide Tracker logs every change.

What the research shows

All of it is research-stage. FDA found no approved product containing kisspeptin-10 in any country ³.

Kisspeptin-10, per FDA's 2024 review [3]:

• Four small studies in people with idiopathic hypogonadotropic hypogonadism, a condition where the brain does not send the reproductive signal. They enrolled 4, 12, 6 and 7 people. Most did not show a hormone response.
• One study in men with type 2 diabetes and low testosterone. In 4 men given an 11-hour IV infusion, average LH rose from 3.9 to 20.7 IU/L and total testosterone from 245.1 to 328.8 ng/dL.
• Two studies of how the body handles it, in healthy women and men.
• FDA said it is "not possible to draw any meaningful conclusions" on effectiveness from these studies.
• Nearly all of it used IV dosing. FDA found no studies of injection under the skin or into muscle in men with hypogonadism, the routes proposed for compounding.

Kisspeptin-54, the longer form:

• IVF trigger, 2014: 53 women having IVF got one injection of kisspeptin-54 to trigger egg maturation. Mature eggs were seen at every dose. 12 of 53 had a clinical pregnancy ⁴. A small, early study.
• Low sexual desire, 2022: 32 premenopausal women with hypoactive sexual desire disorder had a kisspeptin-54 IV infusion and a placebo infusion, in random order. Kisspeptin changed brain activity on scans in response to sexual images, and was reported as well tolerated ⁵.

Both are small, short trials of a different peptide than the one on the list. We found no trial showing that kisspeptin-54 results apply to kisspeptin-10.

Side effects and FDA's concerns

FDA's stated concerns, from its Category 2 page ¹:

• Immune reactions. It "may pose risk for immunogenicity for certain routes of administration."
• Impurities. Complexities with peptide-related impurities and characterizing the substance.
• Thin data. No, or only limited, safety information for the proposed routes.

From FDA's 2024 briefing ³:

• Human exposure: about 300 people across studies, mostly small and short. No serious adverse events were reported, but adverse event data were often missing.
• One FDA adverse event report: a 17-year-old male given 100 mcg under the skin daily for 6 weeks gained weight and had a rise in estrone.
• In mice: in a mouse strain prone to artery disease, 4 weeks of infusion sped up atherosclerosis at both doses tested. FDA called the relevance to people unclear.
• In dogs: 14 days of IV doses showed no drug-related effects.
• Missing studies: no genetic toxicity, reproductive toxicity or cancer studies found. No immune response studies found.
• Stability: sensitive to moisture and light.

Why it's sold online anyway

FDA's briefing found compounder websites listing kisspeptin-10 injections and a troche, and other sites selling 10 mg "research use" vials ³. A "research use only" label is the seller saying the product is not for people.

What those products skip:

• A prescriber reviewing your health history.
• A licensed pharmacy compounding for one patient.
• Any quality check for human use.

The impurity limits FDA saw on one certificate did not describe what the impurities were ³. More: Prescription vs Research Peptides.

Other Shelf 5 pages: thymosin alpha-1, another peptide FDA's panel voted down, and GHK-Cu, the most split status on the shelf.

Asked a lot.

The sources.

1. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). Read it
2. FDA. Pharmacy Compounding Advisory Committee, Oct 29, 2024, meeting minutes. Read it
3. FDA. Pharmacy Compounding Advisory Committee, Oct 29, 2024, briefing document 5: kisspeptin-10. Read it
4. Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014. Read it
5. Thurston L, Hunjan T, Ertl N, et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open. 2022;5(10). Read it
6. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). Read it
7. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026; scheduled to publish in the Federal Register Oct 30, 2026). Read it